Drug intelligence / Profile preview

anti-CD22-41BB CAR-T

Development stage: Unknown
Lead developer: Xuzhou Medical University
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

anti-CD22-41BB CAR-T is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by Xuzhou Medical University for the treatment of B-cell malignancies. The therapy consists of T cells genetically engineered to express a CAR comprising an anti-CD22 single-chain variable fragment (scFv) linked to a 4-1BB (CD137) costimulatory domain and a CD3-zeta signaling domain. In clinical trials, this agent is primarily evaluated as part of a 'mixed infusion' or 'cocktail' strategy, where it is administered simultaneously with an anti-CD19 CAR-T cell product (αCD19-TCRz-41BB). This dual-targeting approach is designed to prevent tumor escape and reduce the incidence of relapse associated with CD19 antigen loss in patients with refractory or recurrent B-cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphoma.

Other names: CD22-41BB CAR-TCD-22-41BB CAR-TCD 22-41BB CAR-Tanti-CD22 CAR-T cellsanti-CD-22 CAR-T cellsanti-CD 22 CAR-T cellsanti-CD22-41BB CAR-T-Xuzhou Medical Universityanti-CD-22-41BB CAR-T-Xuzhou Medical Universityanti-CD 22-41BB CAR-T-Xuzhou Medical University

Targets

CD22 (Cluster of Differentiation 22)TNFRSF9 (CD137 extracellular domain)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on anti-CD22-41BB CAR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-CD22-41BB CAR-T.

Explore the full profile